Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: michael modeme who wrote (460)	12/9/1999 9:17:00 PM
From: Casaubon	Read Replies (1) \| Respond to of 3044

Well, although there are some new rules to the game, there are others that can not EVER change, such as absorption limitations and toxicity. There are also SAR issues that I suspect can never be adequately addressed through combinatorial approaches. I have personally participated in designing more clinical drug prospects, than your entire company, through "The days of trial-and-error drug design and "rational" drug design", with only a handful of chemists. You can't be serious to think I will be replaced.

To: michael modeme who wrote (460)	12/9/1999 9:55:00 PM
From: tommysdad	Read Replies (3) \| Respond to of 3044

<<The days of trial-and-error drug design and "rational" drug design are for the most part going to be replaced. >> Um, by what?